Cancer Research and Treatment

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors: Jin Seok Ahn, Jung Yong Hong, Joon Oh Park, Sung Young Lee, SuYeon Kim, Hwi-yeol Yun, Chan-Young Ock, Woochan Hwang, Sung Ho Kim, Heung Tae Kim, Ho Yeong Lim; Received August 4, 2025 Accepted November 3, 2025 Published online November 4, 2025; DOI: https://doi.org/10.4143/crt.2025.820 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
IMC-002 is a fully human cluster of differentiation 47-targeted immunoglobulin G4 monoclonal antibody, designed to minimize off-target effects. This study (NCT05276310) assessed its safety/tolerability and preliminary anti-tumor activity in patients with advanced solid tumors who were not eligible for or had progressed on standard treatment.
Materials and Methods
We report results from the initial 3+3 design dose-escalation part of a two-part phase 1, open-label, dose-escalation/expansion study. IMC-002 was administered intravenously every 2 weeks at four doses (5, 10, 20, and 30 mg/kg). The primary objective was to assess safety/tolerability, including maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary objectives included pharmacokinetics and clinical activity, including best overall response (BOR), disease control rate (DCR), and clinical benefit rate (CBR).
Results
Twelve patients were included in total, with three per dose level. Most patients (11/12) had stage IV disease; 7/12 had received three prior systemic therapies. No dose-limiting toxicities were observed and MTD was not reached. The most common treatment-related adverse events were rash (9/12), vitreous floaters (8/12), and (hemolytic) anemia (5/12). There was no treatment-related thrombocytopenia, neutropenia, or infection. IMC-002 had dose-proportional pharmacokinetics, achieving steady state levels from cycle 2. BOR was stable disease in six patients (DCR 50.0%). CBR was 33% (four patients maintaining disease control for ≥ 6 months).
Conclusion
IMC-002 demonstrated favorable safety/tolerability at doses of 5-30 mg/kg every 2 weeks. RP2D was defined as 20 mg/kg every 3 weeks. Preliminary anti-tumor activity was observed, with a CBR of 33%.

Citations

Citations to this article as recorded by

The CD47 signaling axis regulates the formation and vulnerability of atherosclerotic plaques: mechanism analysis and targeting strategies
Liyang Bai, Baofeng Xu, Ying Chen, Dan Fu, Lijuan Wang, Di Ma
Frontiers in Immunology.2026;[Epub] CrossRef
Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding
Tae‐Shin Kim, Jae Hyeon Park, Yousun Chung, Dae‐Hyun Ko, Seon Young Kim, Hyungsuk Kim
Transfusion.2026;[Epub] CrossRef

1,995 View
136 Download
2 Crossref

A Case of Extraskeletal Ewing's Sarcoma Arising from Duodenum: Sang Il Kim, Yeon Hee Park, Seong Jun Choi, Baek Yeol Ryoo, Seung Sook Lee, Hyun Bae Son, Yo Ahn Suh, Dae Han Kim, Sung Ho Kim, Kui Sung Choi, Yoong Ju Kweon; Cancer Res Treat. 2002;34(6):461-465. Published online December 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.6.461

Abstract PDF

Extraskeletal Ewing's sarcomas (EES) are rare. Recently, Ewing's sarcoma of the bone, primitive neuroectodermal tumor (PNET), Askin tumor and EES have been included into the family of Ewing's tumors, due to the overlapping features relating to their clinico-pathological and cytogenetic appearance. We experienced a case of an EES arising from the duodenum in a 14-year-old girl who presented with hematemesis and epigastric discomfort. A duodenal biopsy specimen revealed the infiltration of small round cells and rich vasculatures, with immunohistochemical finding of MIC-2 (CD99) (+), vimentin (+), CD56 (NCAM) (+), LCA (-), T-cell (-), B-cell (-), CD43 (-) and CD68 (-). She was treated with several cycles of multiagent chemotherapy, and achieved an initial partial response, but rapid progression of tumor followed, so she was treated with surgical excision. This is the first case report of an EES arising from the duodenum in the literature.

Citations

Citations to this article as recorded by

“Ewing’s sarcoma of the duodenum: a rare gastrointestinal presentation”: case report and review of literature
Sujata Agrawal, Paramita Paul
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Ewing’s sarcoma of the duodenum: a rare clinical condition managed with surgical resection
Saniya Saiyed, Omar A Mownah, Matthew J Bowles, Aditya Kanwar
BMJ Case Reports.2023; 16(6): e249686. CrossRef

5,712 View
48 Download
2 Crossref

The Effect of Intensified Induction Using Vanderbilt Regimen in Patients with an Intermediate Grade Non-Hodgkin's Lymphoma Having 2 or 3 Adverse Factors on the Age-adjusted International Prognostic Index: Yoong Ju Kweon, Seong Jun Choi, Baek Yeol Ryoo, Yeon Hee Park, Bong Seog Kim, Dae Han Kim, Sang Il Kim, Sung Ho Kim, Yo Ahn Suh, Hyun Bae Son, Kui Sung Choi, Seung Sook Lee, Yoon Koo Kang; Cancer Res Treat. 2002;34(5):326-333. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.326

Abstract PDF: PURPOSE
The purpose of our study was to evaluate the outcome of intensified induction therapy using the Vanderbilt regimen in patients with a poor prognosis non-Hodgkin's lymphoma (NHL).
MATERIALS AND METHODS
We retrospectively analyzed the results of two pilot studies, which enrolled the patients aged 60 years or less, with a previously untreated NHL of intermediate grade on the Working formulation, having 2 or 3 adverse prognostic factors on the age- adjusted International Prognostic Index. Patients received an intensified induction, with the regimen described by the Vanderbilt group.
RESULTS
Thirty-five patients were analyzed. After induction, 29 patients (83%) achieved more than partial response (PR): 22 (63%) complete response (CR) and 7 (20%) PR. Three of the PRs were subsequently converted to CR following consolidation therapy. The overall CR rate, following the completion of treatment, was 71%. The 3-year overall survival (OS) rate of all patients was 53%. In the univariate analysis, age (50 years) was the only factor affecting the OS. The 3-year disease-free survival (DFS) rate of patients with CR was 68%. In the univariate analysis, age and bone marrow involvement were the factors affecting the DFS. Two patients died from the treatment-related toxicity of the induction therapy: one due to sepsis and the other due to congestive heart failure.
CONCLUSION
Although the CR rate was relatively high, the OS or DFS of patients with a poor prognosis NHL, who had received the intensified induction using the Vanderbilt regimen, were no different from those that had received the conventional chemotherapy, as reported by the International Prognostic Index Project. However, the OS or DFS in the young patient groups were encouraging. To test the hypothesized benefits of our approach in the young patient groups, a larger cohort of patients aged 50 years or less should be studied.

4,453 View
25 Download

Inhibition of Development of Benzo(a)purene-induced Mouse Pulmonary Adenoma by Several Natural Products in medium-term Bioassay System: Taik Koo Yun, Sung Ho Kim; J Korean Cancer Assoc. 1988;20(2):133-143.

Abstract PDF: The present experiment adopted the nine week medium-term bioassay system that was established at the auturs' laboratory. In the nine week medium-term assay system,500 ug of benzo(a)pyrene were injected to non-inbred NIH

2,990 View
18 Download

Lack of Modifying Effect of Germanium in Rat Hepatic Foci Initiated by Diethylnitrosamine Followed by D - Galactosamine Treatment: Ja June Jang, Sun Ju Lee, Kyung Ja Cho, Sung Ho Kim; J Korean Cancer Assoc. 1989;21(1):7-11.

Abstract PDF: The modification potentials of germanium on the development of preneoplastic hepatic enzyme altered foci were examined in an in vivo midterm assay system. Two week after the initial single ip dose(200 mg/kg) of diethylnitrosamine (DEN), administration of germanium at a concentration of 0.05% on the diet was commenced simultaneously with an ip injection of D-galactosamine at a dose of 300 mg/kg body wt. A11 rats were subjected to two thirds partial hepatectomy at week 5 and sacrificed for assessment of lesion yield at week 8. The modifying potential was scored by comparing the number and area per cm* of induced glutathione S-transferase placental farm-positive (GST-P) foci in the liver with those of the corresponding control group given DEN alone. Germanium showed no statistically significant increase in the number, area and mean diameter of GST-P+ foci.

2,529 View
15 Download

Medium - term ( Nine weeks Method for Assay of Preventive Agents Against Tumors: Taik Ku Yun, Sung Ho Kim, Yeong Ran Oh; J Korean Cancer Assoc. 1987;19(1):1-8.

Abstract PDF: For short-term carcinogenesis experirnents using animals, a method studying the incidence of pulmonary adenoma in newborn mice has been generally adopted, but this method still needs mote than 24 weeks. This expenment is one of the attempts to make such experiment period shorter. In this experimeit, both'inbred mice such as C57BL/6J, C57BR/cdJ, A/J strain and non- inbred NIH(GP) strain were used. Each mouse group was sacrificed nine weeks after a single injection of benzo(a)pyrene into subscapular region within 24 hours after birth. In C57BL/6J or C57BR/cdJ mice, no pulmonary adenoma was observed at either normal control group or bepzo(a)pyrene-injected groups by 0. 5 mg or I mg. In A/J inbred mice, however, the incidences of pulmonary adenoma were 3.9 per cent at normal control group, 86,7 per cent at 0.5 mg benzo(a)pyreae group and 88. 3 per cent at I mg benzo(a)pyrene group, respectively. In non-inbred NiH(GP) mice, the incidences were 2.5 per cent at normal group, 46. 8 per cent at 0. 5 mg group and 54. 4 per cent at 1 mg group, respectively. To verify he utility of this experiment, an NIH(GP) newborn mouse group, after inje- ction of 500 pw of benzo(a)pyrene, was administered ascorbric acid through drinking water for six weeks after they were weaned. it was observed that the pulmonary adenoma incidence was 46.8 per cent at the group injected 500 ug of benzo(a)pyrene only wbile it was decreased to 29. 5 per cent at the group administered both SQl pg of benso(a)pyrene and ascorbic acid, thus showed 37 per cent of the Prevention effect. It was proved from the above result that this method was useful to detect anticarcinogenes.

2,691 View
16 Download

Effects of Copolang on Murine Immune Fuction and Antitumor Activity: Sung Kee Jo, Sung Ho Kim, Taik Ku Yun; J Korean Cancer Assoc. 1987;19(1):28-36.

Abstract PDF: The examinations were conducted with Copolang (protein bound polysaccharides from na- tural Coriolus versicolor) and PSK(protein bound polysaccharides from cultured Coriolas versicolar) referring to anti-tumor effect on several experimental tumor lines, influence on host immune function and its toxicity. Acute toxicity of Copolang could not be observed because the case of death was occured at higher dose administrations. There were significant inhibition of tumor growth in Sarcoma 180 by intraperitoneal administration of Copolang or PSK compared with control(p<0.01), Two cases of complete tumor regression was observed in the Copolang or PSK,treatment group. However, the results indicated that Copolang or PSK did not inhibit the growth of L1210 solid tumor and not prolonged life span of L1210 or P 388 tumor bearing mice. Natural killer ce11 activities of splenic lymphocytes and non-adherent peritoneal exudate cells were augmented by Copolang administration in EL-4 transplanted C57BL/6 mice. Cytoto.xicity of T lymphocyte against EL-4 was enhanced by Copolang in the tumor-bearing mice.

2,779 View
15 Download

Search